IMBRUVICA® is an oral, once-daily, single-agent therapy associated with a durable response in patients with this rare B-cell lymphoma
Toronto, ON – May 12, 2016 – Janssen Inc. announced today that Health Canada has issued a Notice of Compliance (NOC) for IMBRUVICA® (ibrutinib), an oral, once-daily, single-agent therapy for the treatment of patients with Waldenström’s macroglobulinemia (WM).1 Waldenström’s macroglobulinemia is a rare, incurable type of non-Hodgkin lymphoma, a cancer that begins in the body’s immune system.2,3
IMBRUVICA® was first approved in Canada in November 2014 for the treatment of patients with chronic lymphocytic leukemia (CLL), including those with 17p deletion, who have received at least one prior therapy, or for the frontline treatment of patients with CLL with 17p deletion. In July 2015, IMBRUVICA® was approved with conditions for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
“Before now, treatment options for my patients with Waldenström’s macroglobulinemia have been limited,” said Dr. David Macdonald, MD, FRCPC, Assistant Professor, Dalhousie University, Hematologist, Capital Health. “The approval of IMBRUVICA® is a major advancement as this agent offers a targeted, chemotherapy-free treatment option for patients with WM, as it has done for those with other B-cell malignancies. It has shown clinically meaningful outcomes for these patients, as demonstrated by a high overall response rate.”
The Canadian Organization for Rare Disorders Hereby Gives Notice of its Annual General Meeting: August 26, 2024 at 2:00 PM (EDT) via videoconference
CORD Annual General MeetingAugust 26, 2024 at 2:00 PM (EDT) via videoconference Dear CORD Members: The Canadian Organization for Rare Disorders gives notice of it's Annual General Meeting on August 26, 2024 at 2pm - 3pm (Eastern Time). All individual, affiliate and corporate members in good standing are invited participate. An eligible voter must be a representative of a voting member of CORD. Eligible voters may either vote at the upcoming Annual General Meeting videoconference or by proxy. Votes by proxy must be in must be returned to us by August 25, 2024. Ballots received after this date and time, duplicate votes and spoiled ballots will not be counted. To participate in the AGM teleconference, please register by August 25, 2024 Registration: https://bit.ly/4aM8IJL Once we have received your response, we will email you the teleconference details and any other necessary documents that will be required for the meeting. Thank you for your participation and if you have any questions, please let me know. Sincerely, Christine White CORD Secretary PROXY-2024Download
The Canadian Organization for Rare Disorders Hereby Gives Notice of its Annual General Meeting: August 26, 2024 at 2:00 PM (EDT) via videoconference
CORD Annual General MeetingAugust 26, 2024 at 2:00 PM (EDT) via videoconference Dear CORD Members: The Canadian Organization for Rare Disorders gives notice of it's Annual General Meeting on August 26, 2024 at 2pm - 3pm (Eastern Time). All individual, affiliate and corporate members in good standing are invited participate. An eligible voter must be a representative of a voting member of CORD. Eligible voters may either vote at the upcoming Annual General Meeting videoconference or by proxy. Votes by proxy must be in must be returned to us by August 25, 2024. Ballots received after this date and time, duplicate votes and spoiled ballots will not be counted. To participate in the AGM teleconference, please register by August 25, 2024 Registration: https://bit.ly/4aM8IJL Once we have received your response, we will email you the teleconference details and any other necessary documents that will be required for the meeting. Thank you for your participation and if you have any questions, please let me know. Sincerely, Christine White CORD Secretary PROXY-2024Download
Join us and become part of an active Canadian rare disorder community. The only national organization representing all rare disorder patient groups in Canada.
LEARN MORE